Traditional Chinese medicine tea composition for improving viral pneumonia as well as preparation method and application of traditional Chinese medicine tea composition

Abstract

The invention provides a traditional Chinese medicine tea composition for improving viral pneumonia and a preparation method and application thereof, and relates to the technical field of traditional Chinese medicine, the traditional Chinese medicine tea composition comprises the following components: 11-18 parts of perilla leaf, 7-13 parts of honeysuckle, 7-13 parts of polygonatum odoratum, 5-12 parts of scorched hawthorn fruit, 4-8 parts of platycodon grandiflorum, 3-7 parts of pericarpium citri reticulatae, 3-7 parts of liquorice, 3-7 parts of chrysanthemum, 2-5 parts of osmanthus fragrans, 0.3-0.6 part of stevia rebaudiana, and 6-14 parts of black tea. An anti-inflammatory effect experiment of THP-1 cells proves that the traditional Chinese medicine tea composition has an improvement effect on viral pneumonia, specifically, the traditional Chinese medicine tea composition can effectively reduce IL-6 expression and has good anti-inflammatory activity; the expression of inflammatory indexes NO and IL-6 of RAW264.7 cells induced by lipopolysaccharide LPS is obviously reduced; the traditional Chinese medicine tea composition can be applied to preparation of anti-virus pneumonia products.

Description

Technical Field

[0001] The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine tea composition for improving viral pneumonia, a preparation method and an application thereof. Background Art

[0002] Viral pneumonia is an inflammatory disease characterized by varying degrees of lung parenchymal damage caused by viruses invading the respiratory and alveolar epithelium. Causative pathogens include influenza virus, coronavirus, measles virus, respiratory syncytial virus, adenovirus, and rhinovirus. Viral pneumonia often causes varying degrees of hypoxia and infection, typically with fever, cough, wheezing, shortness of breath, and crackles in the lungs, along with abnormal chest imaging. In severe cases, pulmonary interstitial fibrosis, respiratory failure, and even life-threatening conditions may develop. Patients are often elderly and children with frail constitutions.

[0003] In recent years, with the deepening of Traditional Chinese Medicine (TCM) research, TCM has demonstrated unique advantages and potential in treating viral pneumonia, with several drugs proven to be effective. For example, honeysuckle is a commonly used herb in TCM clinical practice for clearing heat and detoxifying. A study on viral pneumonia caused by influenza virus demonstrated that honeysuckle possesses broad-spectrum antibacterial properties, effectively combating potential bacterial infections.

[0004] Traditional Chinese medicine (TCM) not only focuses on the efficacy of individual herbs in treating viral pneumonia, but also emphasizes the synergistic effects of multiple herbs. Through appropriate combinations, TCM can achieve even greater therapeutic benefits. For example, in a study targeting the novel coronavirus, the TCM formula "Qingfei Paidu Decoction" demonstrated promising therapeutic results. This formula, which includes ephedra, apricot kernel, gypsum, and licorice, among other herbs, is known to clear the lungs, relieve coughs, clear away heat, and detoxify, effectively improving patients' clinical symptoms.

[0005] Chinese invention patent CN111214610A discloses a method for preparing a traditional Chinese medicine formula pack for preventing respiratory viral infections. The formula includes bupleurum, asarum, atractylodes, mugwort, rhubarb, houttuynia cordata, notopterygium wilfordii, pseudoginseng, coptis chinensis, and liquorice. The herbal ingredients are dried, crushed, and then mixed to produce the pack. The medicinal aroma emitted by the pack can prevent various viral infections, including coronaviruses, typhoid bacilli, Vibrio cholerae, and avian influenza, and can enhance human immunity. However, the pack is only suitable for wearing or placing in the environment, and its effectiveness is limited.

[0006] Chinese invention patent CN117205291A discloses an application of a composition for improving respiratory immunity in the preparation of antiviral pneumonia drugs, the formula including: 50-150 parts of honeysuckle, 20-80 parts of dried tangerine peel, 10-50 parts of emblica fruit, 10-50 parts of licorice, 10-30 parts of yam, 10-30 parts of mint, 10-30 parts of glabrous vine leaves, 5-15 parts of perilla seeds, 5-15 parts of momordica grosvenori, 1-5 parts of Yunnan small yellow ginger, 12-48 parts of turmeric and 20-80 parts of black pepper. The invention proves that the composition has antiviral pneumonia efficacy through antiviral pneumonia zebrafish experiments, which is specifically manifested in the efficacy of improving neutrophil aggregation, improving macrophage aggregation, improving T cell reduction and improving the degree of lesions in the swim bladder. However, the raw materials of the composition are not all medicinal and edible medicinal materials, the safety of long-term use is unknown, and it is also inconvenient to take.

[0007] Zou Min et al. (Research Progress on the Treatment of Viral Pneumonia with Traditional Chinese Medicine [J]. Medical Theory and Practice, 2023, 36(21): 3630-3632) believe that viral pneumonia in traditional Chinese medicine is characterized by fever, cough, phlegm accumulation, and shortness of breath as the main clinical symptoms. Traditional Chinese medicine has significant advantages in the treatment of acute viral pneumonia, early intervention, recovery period conditioning, and improving prognosis. Commonly used traditional Chinese medicine decoctions for the treatment of viral pneumonia include Qingfei Paidu Decoction, Maxing Shigan Decoction, and Huashi Jiedu Decoction. However, the interactions between the components of the above-mentioned prescriptions are still unknown, and most of them do not show synergistic effects.

[0008] Therefore, it is necessary to select medicinal and edible medicinal materials for scientific combination based on ancient classic prescriptions and pharmacological experimental data to prepare a Chinese herbal tea composition that has the effect of preventing and treating inflammation, is easy to drink, has high safety, and is suitable for people of different ages. Summary of the Invention

[0009] The present invention addresses the problems existing in the prior art and provides a Chinese herbal tea composition for improving viral pneumonia, as well as a preparation method and application thereof. Pharmacological experiments have shown that the Chinese herbal tea composition of the present invention has a good anti-inflammatory effect and can effectively improve the degree of inflammation. The raw materials are safe and easily available, and the composition is easy to take, thereby having a good application prospect.

[0010] To achieve the above object, the technical solution adopted by the present invention is as follows: On the one hand, the present invention provides a traditional Chinese medicine tea composition for improving viral pneumonia. The components include, by weight, 11-18 parts of perilla leaves, 7-13 parts of honeysuckle, 7-13 parts of polygonatum, 5-12 parts of charred hawthorn, 4-8 parts of platycodon, 3-7 parts of tangerine peel, 3-7 parts of licorice, 3-7 parts of chrysanthemum, 2-5 parts of osmanthus, 0.3-0.6 parts of stevia and 6-14 parts of black tea.

[0011] Preferably, the Chinese herbal tea composition comprises, by weight, 15 parts of perilla leaves, 10 parts of honeysuckle, 10 parts of polygonatum, 8 parts of charred hawthorn, 6 parts of platycodon, 5 parts of tangerine peel, 3 parts of licorice, 5 parts of chrysanthemum, 3 parts of osmanthus, 0.4 part of stevia and 11 parts of black tea.

[0012] Preferably, the Chinese herbal tea composition is composed of the following components, in parts by weight: 11-18 parts of perilla leaves, 7-13 parts of honeysuckle, 7-13 parts of polygonatum, 5-12 parts of charred hawthorn, 4-8 parts of platycodon, 3-7 parts of tangerine peel, 3-7 parts of licorice, 3-7 parts of chrysanthemum, 2-5 parts of osmanthus, 0.3-0.6 parts of stevia and 6-14 parts of black tea.

[0013] Further preferably, the Chinese herbal tea composition is composed of the following components, in parts by weight: 15 parts of perilla leaves, 10 parts of honeysuckle, 10 parts of polygonatum, 8 parts of charred hawthorn, 6 parts of platycodon, 5 parts of tangerine peel, 3 parts of licorice, 5 parts of chrysanthemum, 3 parts of osmanthus, 0.4 part of stevia and 11 parts of black tea.

[0014] Then, the present invention provides a method for preparing the above-mentioned Chinese medicinal tea composition, comprising the steps of: (1) Dry, crush and sieve perilla leaves, honeysuckle, polygonatum, charred hawthorn, platycodon, tangerine peel, liquorice, chrysanthemum and stevia; dry osmanthus and black tea; (2) The ingredients of step (1) are mixed and sieved to obtain a Chinese herbal tea composition.

[0015] Preferably, the mesh size of the sieving in step (1) is 30-60 meshes.

[0016] Preferably, in step (1), the osmanthus and black tea are dried, and after drying, the step of crushing and screening is further included, and the mesh size of the screening is 30-60 mesh.

[0017] Preferably, in step (2), a packaging step is also included.

[0018] Further preferably, the packaging steps are specifically as follows: adding the obtained Chinese herbal tea composition into the hopper of an automatic feeding machine, setting the weight of each bag, and putting it into small tea bags as inner packaging; the tea bags are made of non-woven fabric; the small tea bags pass through an automatic metal foreign body detector to automatically remove small packaging bags containing metal foreign bodies; the tea bags are put into an outer packaging box, and the box is closed after arranging them neatly; a film is added to the outside of the box, and the box is fed into a packaging machine. The film is wrapped around the outside of the box, and then the film is cut and blown towards the film by hot air. After the film is heated, it shrinks and tightly wraps around the surface of the box to form a complete package.

[0019] During the packaging of the Chinese medicinal tea composition of the present invention, the weight of each package can be an appropriate weight, for example, 1-10g; not limited to 1g, 2g, 3g, 4g, 5g, 6g, 7g, 8g, 9g, 10g.

[0020] Furthermore, the present invention provides the use of the above-mentioned Chinese medicinal tea composition in preparing a product having the efficacy of improving viral pneumonia.

[0021] Finally, the present invention provides a product with the efficacy of improving viral pneumonia, comprising the above-mentioned Chinese medicinal tea composition.

[0022] Preferably, the products include Chinese herbal tea, Chinese herbal granules, and Chinese herbal beverages.

[0023] The Chinese medicinal tea composition of the present invention is explained as follows: Perilla leaves can invigorate the lungs, disperse external pathogens, and relieve phlegm and cough; honeysuckle clears heat and detoxifies, and soothes the throat; Polygonatum odoratum nourishes yin and moistens the lungs, relieves cough and resolves phlegm, and can also promote fluid production and quench thirst; Platycodon grandiflorum clears the lungs and resolves phlegm, promotes lung function and relieves sore throat; chrysanthemum dispels wind and dissipates heat, clears heat and reduces swelling; tangerine peel strengthens the spleen and regulates the middle, promotes qi and resolves phlegm; charred hawthorn regulates qi, aids digestion, and resolves accumulation; licorice replenishes qi and nourishes the middle, removes phlegm and relieves cough, and harmonizes all the medicines; stevia promotes fluid production and quenches thirst; black tea refreshes the mind, relieves fatigue, promotes fluid production and clears heat; and seasonal osmanthus is used for flavoring and fragrance.

[0024] Compared with the prior art, the present invention has the following beneficial effects: (1) The Chinese herbal tea composition of the present invention controls the ratio of each medicinal material so that the components can better interact with each other, thereby enhancing the efficacy of treating viral pneumonia, significantly reducing NO secretion and IL-6 concentration, and having excellent anti-inflammatory effects.

[0025] (2) The Chinese herbal tea composition of the present invention has clear chemical components, and the components cooperate with each other to achieve synergistic effects, thereby bringing about significant anti-inflammatory effects.

[0026] (3) The Chinese herbal tea composition of the present invention uses ingredients that are both medicinal and edible. The raw materials are readily available and highly safe, making it suitable for long-term use by the general public. The tea soup is bright in color and has a mellow and sweet taste. It is more durable and compliant than taking decoctions, and can be combined with daily tea drinking for medical treatment and health care. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 Results of NO secretion under different drug administration conditions.

[0028] Figure 2 The results of the anti-inflammatory effect of IL-6 under different administration conditions.

[0029] Figure 3Expression of NO and IL-6 in RAW264.7 cells after administration of drug-containing rat serum, where (A) is the expression of IL-6 and (B) is the expression of NO. DETAILED DESCRIPTION

[0030] The following non-limiting examples are provided to enable those skilled in the art to more fully understand the present invention, but are not intended to limit the present invention in any way. The following are merely illustrative of the scope of the present invention, and those skilled in the art may make various changes and modifications to the present invention based on the disclosed content, which should also fall within the scope of the present invention.

[0031] When numerical ranges are given in the examples, it should be understood that, unless otherwise specified herein, both endpoints of each numerical range and any value between the two endpoints may be selected. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the invention belongs.

[0032] The present invention is further illustrated below by way of specific examples. In the following examples, the raw materials were sourced as follows: Perilla leaf (20230620) and honeysuckle (20230922) were from Hangzhou, Zhejiang; osmanthus (C23090718) and stevia (2308011671) were from Anguo, Hebei; and dried tangerine peel (23080901), liquorice (23082104), charred hawthorn (23081601), platycodon (23070503), chrysanthemum (23071901), and polygonatum (23030203) were from Shaoxing, Zhejiang.

[0033] In the following embodiments of the present invention, the herbal tea composition can be prepared as herbal tea, and the components, in parts by weight, include: 11-18 parts of perilla leaves, 7-13 parts of honeysuckle, 7-13 parts of polygonatum, 5-12 parts of charred hawthorn, 4-8 parts of platycodon, 3-7 parts of tangerine peel, 3-7 parts of liquorice, 3-7 parts of chrysanthemum, 2-5 parts of osmanthus, 0.3-0.6 parts of stevia and 6-14 parts of black tea.

[0034] In some embodiments, the herbal tea composition can be prepared as herbal tea, and the components in parts by weight include: 15 parts of perilla leaves, 10 parts of honeysuckle, 10 parts of polygonatum, 8 parts of charred hawthorn, 6 parts of platycodon, 5 parts of tangerine peel, 3 parts of licorice, 5 parts of chrysanthemum, 3 parts of osmanthus, 0.4 parts of stevia and 11 parts of black tea.

[0035] In some embodiments, the method of drinking the herbal tea is: Add one tea bag (3g of the herbal tea composition) to 200-1000mL of drinking water and boil for 10-30 minutes before drinking. Alternatively, place one tea bag (3g of the herbal tea composition) in drinking water of a preset volume (200-1000mL) and temperature (80-100°C) and soak for 5-20 minutes before drinking. Repeat the process with the above drinking water. Consume 1-2 bags daily.

[0036] Example 1 A Chinese medicinal tea composition for improving viral pneumonia as both medicine and food, comprising the following components in parts by weight: 15 parts of perilla leaves, 10 parts of honeysuckle, 10 parts of polygonatum, 8 parts of charred hawthorn, 6 parts of platycodon, 5 parts of dried tangerine peel, 3 parts of liquorice, 5 parts of chrysanthemum, 3 parts of osmanthus, 0.4 part of stevia, and 11 parts of black tea.

[0037] The preparation method of the above-mentioned Chinese medicinal tea composition comprises the steps of: (1) Dry and crush the perilla leaves, honeysuckle, polygonatum, charred hawthorn, platycodon, tangerine peel, liquorice, chrysanthemum and stevia, pass through a 60-mesh sieve to remove fine powder; dry the osmanthus and black tea, pass through a 30-mesh sieve to remove fine powder; (2) Mixing the ingredients of step (1) to obtain a Chinese herbal tea composition.

[0038] Example 2 A Chinese medicinal tea composition for improving viral pneumonia as both medicine and food, comprising the following components in parts by weight: 11 parts of perilla leaves, 7 parts of honeysuckle, 7 parts of polygonatum, 5 parts of charred hawthorn, 4 parts of platycodon, 3 parts of tangerine peel, 3 parts of liquorice, 3 parts of chrysanthemum, 2 parts of osmanthus, 0.3 part of stevia, and 6 parts of black tea.

[0039] The preparation method is the same as that of Example 1.

[0040] Example 3 A Chinese medicinal tea composition for improving viral pneumonia as both medicine and food, comprising the following components in parts by weight: 18 parts of perilla leaves, 13 parts of honeysuckle, 13 parts of polygonatum, 12 parts of charred hawthorn, 8 parts of platycodon, 7 parts of dried tangerine peel, 7 parts of liquorice, 7 parts of chrysanthemum, 5 parts of osmanthus, 0.6 part of stevia, and 14 parts of black tea.

[0041] The preparation method is the same as that of Example 1.

[0042] Comparative Example 1 The difference from Example 1 is that the ingredients of the Chinese herbal tea composition are different, specifically: the chrysanthemum ingredient is replaced by houttuynia cordata.

[0043] The Chinese herbal tea composition comprises the following components in parts by weight: 15 parts of perilla leaves, 10 parts of honeysuckle, 10 parts of polygonatum, 8 parts of charred hawthorn, 6 parts of platycodon, 5 parts of tangerine peel, 3 parts of liquorice, 5 parts of houttuynia cordata, 3 parts of osmanthus, 5 parts of yam, 0.4 part of stevia and 11 parts of black tea.

[0044] The preparation method is: (1) Dry and crush the perilla leaves, honeysuckle, polygonatum, charred hawthorn, platycodon, tangerine peel, liquorice and stevia, pass through a 60-mesh sieve to remove fine powder; dry the osmanthus and black tea, pass through a 30-mesh sieve to remove fine powder; (2) Mixing the ingredients of step (1) to obtain a Chinese herbal tea composition.

[0045] Comparative Example 2 The difference from Example 1 is that the ingredients of the Chinese medicinal tea composition are different, specifically: Chinese yam ingredient is added.

[0046] The Chinese herbal tea composition comprises the following components in parts by weight: 15 parts of perilla leaves, 10 parts of honeysuckle, 10 parts of polygonatum, 8 parts of charred hawthorn, 6 parts of platycodon, 5 parts of tangerine peel, 3 parts of liquorice, 5 parts of chrysanthemum, 3 parts of osmanthus, 0.4 part of stevia, 11 parts of black tea and 5 parts of yam.

[0047] The preparation method of the Chinese medicinal tea composition is: (1) Dry and crush the perilla leaves, honeysuckle, polygonatum, charred hawthorn, platycodon, tangerine peel, liquorice, chrysanthemum, stevia and Chinese yam, pass through a 60-mesh sieve to remove fine powder; dry the osmanthus and black tea, pass through a 30-mesh sieve to remove fine powder; (2) Mixing the ingredients of step (1) to obtain a Chinese herbal tea composition.

[0048] Comparative Example 3 The difference from Example 1 is that the ingredients of the Chinese herbal tea composition are different: The components of the Chinese medicinal tea composition are as follows: 15 parts of perilla leaves, 10 parts of honeysuckle, 5 parts of tangerine peel and 3 parts of liquorice in parts by weight.

[0049] The preparation method of the Chinese medicinal tea composition is: The perilla leaves, honeysuckle, tangerine peel and liquorice are dried, crushed, passed through a 60-mesh sieve, and fine powder is removed to obtain a Chinese medicinal tea composition.

[0050] Comparative Example 4 The difference from Example 1 is that the ingredients of the Chinese herbal tea composition are different, specifically: The components of the Chinese medicinal tea composition are as follows: 10 parts of polygonatum, 8 parts of charred hawthorn, 6 parts of platycodon, 5 parts of chrysanthemum, 3 parts of osmanthus, 0.4 part of stevia and 11 parts of black tea.

[0051] The preparation method of the Chinese medicinal tea composition is: (1) Dry and crush the polygonatum, charred hawthorn, platycodon grandiflorum, chrysanthemum, stevia and black tea, pass through a 60-mesh sieve to remove fine powder; dry the osmanthus and black tea, pass through a 30-mesh sieve to remove fine powder; (2) Mixing the ingredients of step (1) to obtain a Chinese herbal tea composition.

[0052] Comparative Example 5 The difference from Example 1 is that the weight ratio of the Chinese medicinal tea composition is different.

[0053] The components of the Chinese herbal tea composition are as follows: 7 parts of perilla leaves, 16 parts of honeysuckle, 5 parts of polygonatum, 8 parts of charred hawthorn, 7 parts of platycodon, 5 parts of tangerine peel, 3 parts of liquorice, 10 parts of chrysanthemum, 3 parts of osmanthus, 0.4 part of stevia and 11 parts of black tea.

[0054] (1) Dry and crush the perilla leaves, honeysuckle, polygonatum, charred hawthorn, platycodon, tangerine peel, liquorice, chrysanthemum and stevia, pass through a 60-mesh sieve to remove fine powder; dry the osmanthus and black tea, pass through a 30-mesh sieve to remove fine powder; (2) Mixing the ingredients of step (1) to obtain a Chinese herbal tea composition.

[0055] Result detection Test 1: Composition determination 1. Testing conditions and equipment Instruments: AB Sciex Triple TOF 6600+ fast high-performance liquid chromatography-quadrupole time-of-flight mass spectrometry; Waters high-performance liquid chromatograph; BUCHI Roravapor R-200 rotary evaporator; Thermo centrifugal concentrator and freeze dryer.

[0056] Analytical conditions: HPLC mobile phase: water-0.1% formic acid (A), acetonitrile (B). Gradient elution: 0%-6% B (0-9 min); 6%-10% B (9-10 min); 10%-30% B (10-30 min); 30%-0% B (30-30.5 min). Column temperature: 25°C. Injection volume: 10 μL. Flow rate: 0.3 mL / min. Detection wavelength: 203 nm. Quadrupole time-of-flight mass spectrometry detection, ESI source, direct mass spectrometry.

[0057] 2. Ingredient test results The herbal tea composition prepared in the example was subjected to water extraction (10 times the amount of water was boiled for 30 minutes to obtain a water extract), and then the obtained water extract was frozen at -80°C for 12 hours using rotary evaporation (40°C), vacuum freeze-dried to dryness, dissolved in chromatographic-grade methanol, and then subjected to mass spectrometry to analyze its chemical composition.

[0058] The results showed that its main chemical components were alkaloids, flavonoids, organic acids, triterpenoid saponins and phenylpropanoids. Including: Quinic acid, chlorogenic acid, neochlorogenic acid (5-caffeoylquinic acid), caffeic acid, vicenin-2, Liquiritin apioside, rutin, hyperoside, quercitrin, Luteolin-7-O-glucoside, acteoside, Isochlorogenic Acid B, Isochlorogenic Acid C, Apigenin 7-O-glucuronide, chrysin, daidzein, Licochalcone B B), Liquiritigenin, Kaempferol, Luteolin, Apigenin, Oleanolic Acid, Prunin.

[0059] Experiment 2: Activity Prediction First, the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) and the Integrative Pharmacology-based Research Platform of Traditional Chinese Medicine (TCMIP) were used to screen for compounds related to the main components of traditional Chinese medicinal teas. They identified 56 compounds from Perilla frutescens, 56 from Honeysuckle, 9 from Polygonatum odoratum, 30 from Crataegus pinnatifida, 14 from Platycodon grandiflorum, 48 from Citrus reticulatae, 33 from Chrysanthemum, and 180 from Licorice. No compounds from black tea, Osmanthus fragrans, or Stevia rebaudiana met the criteria.

[0060] The compounds were imported into the TCMSP database and their targets were screened. A total of 41 compounds from Perilla frutescens, 44 from Honeysuckle, 6 from Polygonatum odoratum, 14 from Crataegus pinnatifida, 4 from Platycodon grandiflorum, 30 from Citrus reticulatae, 22 from Chrysanthemum, and 103 from Glycyrrhiza uralensis were obtained, for a total of 222 compounds after deduplication.

[0061] Viral pneumonia targets were searched from the OMIM, DrugBank, PGKB, and GeneCards databases. The OMIM search yielded 133 disease targets; the DrugBank search yielded no targets using the keyword "viral pneumonia"; the PGKB search yielded 6 disease targets; and the GeneCards search yielded 5880 disease targets. After deduplication analysis, a total of 5985 viral pneumonia-related targets were obtained.

[0062] Running Veen software in the R4.0.2 language environment, compound-related targets and disease targets were imported separately. After statistical analysis, 284 intersection targets were obtained, including interleukin-6 (IL-6), tumor necrosis factor (TNF), protein kinase B1 (AKT1), and interleukin-1β (IL-1β). Further enrichment analysis showed that these intersection targets mainly involved key pathways related to viral pneumonia, such as inflammatory response and oxidative stress response, suggesting that the Chinese herbal tea composition has a good effect in treating viral pneumonia, and its regulatory effect may be related to the inflammatory response.

[0063] Experiment 3: Comparative study on the anti-inflammatory effects of different Chinese herbal tea compositions on RAW264.7 cells The experimental cells were mouse mononuclear macrophage cell line RAW264.7 cells. Cells were diluted to a cell concentration of 50,000 cells / mL in complete cell culture medium and seeded into 96-well plates at 100 μL per well. The cells were grown in a 37°C, 5% CO2 cell culture incubator for adherent growth. After 24 hours, the cells were divided into groups for testing. The normal control group was cultured in complete cell culture medium. The LPS model group was treated with LPS (200 ng / mL) diluted in complete cell culture medium. The drug intervention groups were incubated with either a dexamethasone solution (final concentration 100 μg / mL, positive control group) or an aqueous extract solution of a Chinese herbal tea composition (final concentration 100 μg / mL) simultaneously with LPS stimulation. After 24 hours of incubation, the cell supernatants were collected and NO secretion was measured using a nitric oxide detection kit.

[0064] Directly transfer 50 μL of cell supernatant from each group to a 96-well plate. Add room-temperature Griess Reagent I and Griess Reagent II to each well at a rate of 50 μL / well. Incubate at room temperature in the dark for 15 minutes. Measure absorbance at 540 nm using a microplate reader. Calculate the nitric oxide concentration in each well based on the standard curve.

[0065] Comparing the concentration of nitric oxide in the supernatant of RAW264.7 cells between the normal control group and the model group (LPS group), it was found that the NO concentration in the LPS group was significantly increased, indicating that the induction of RAW264.7 cells with LPS in the model group would significantly increase the NO expression level of RAW264.7 cells, and the inflammation model was successfully constructed. Comparing the concentration of NO in the cell supernatant after the model group was given extracts of different Chinese herbal tea compositions, it was found that the NO secretion of the positive drug dexamethasone group was significantly reduced, and the cell NO expression level also decreased significantly after the administration of the Chinese herbal tea compositions of Example 1, Example 2 and Example 3, showing a good anti-inflammatory effect. There was no significant difference between the examples. Although the comparison examples 1, 2 and 5 were also reduced to a certain extent compared with the model group, their effect of inhibiting NO secretion was significantly reduced compared with the examples. Comparison examples 3 and 4 did not show obvious anti-inflammatory effects. See the specific NO secretion of each group for details. Figure 1 , compared with the LPS group, P < 0.01, P<0.05; compared with Example 1, ## P < 0.01, # P<0.05.

[0066] Experiment 4: Anti-inflammatory effect of Chinese herbal tea composition on THP-1 cells The experimental cells used were human mononuclear macrophage cell line THP-1 cells. The cell concentration was diluted to 50,000 cells / mL with cell culture medium. The cells were seeded into 96-well plates with 100 μL per well. The cells were grown in a cell culture incubator for 24 hours. After the cells adhered to the wall, they were observed under a microscope and divided into groups for the experiment: ①Blank control group (Group C): Replace the cell culture complete medium; ②Model group (M group): replaced with complete culture medium containing 0.5 μg / mL S protein; ③ Modeling + drug intervention group: The culture medium was replaced with complete culture medium containing 0.5 μg / mL S protein and different concentrations (1000, 500, 200, 100, 50, 20 μg / mL) of Chinese herbal tea extract; ④ Simple drug group: Replace with complete medium containing different concentrations (1000, 500, 200, 100, 50, 20 μg / mL) of water extract of Chinese herbal tea composition. Each group has 3 replicate wells, each well has a volume of 100 μL, and is placed in a cell culture incubator at 37°C and 5% CO2 for 24 hours ( Figure 2 The second half of the data is the interleukin-6 concentration data of the drug-only group).

[0067] Remove the cells from the group cultured for 24 hours in the previous step, aspirate the supernatant, and discard the cells. Seal the supernatant and refrigerate at -20°C overnight. Dilute the capture antibody 1:250 in Coating Buffer (1× PBS) and inoculate 20 μL per well in a 96-well enzyme-linked immunosorbent assay (ELISA) plate. Centrifuge and refrigerate overnight.

[0068] Wash the ELISA plate three times with Wash Buffer (PBS containing 0.05% Tween 20) and blot dry with absorbent paper. Add 20 μL of ELISA / ELISPOT diluent (hereinafter referred to as diluent) to each well, centrifuge, and incubate at room temperature for 1 hour. Prepare IL-6 standards at various concentrations (200, 100, 50, 25, 12.5, 6.25, 3.125, and 0 pg / mL). Wash the ELISA plate once with Wash Buffer and blot dry with absorbent paper. Add 20 μL of the standards and ten-fold diluted supernatant to the corresponding wells, centrifuge, and incubate at room temperature for 2 hours. Wash the ELISA plate three times with Wash Buffer and blot dry with absorbent paper. Dilute the detection antibody 1:250 with diluent and add 20 μL of the detection antibody to the standard and sample wells, centrifuge, and incubate at room temperature for 1 hour. Wash the ELISA plate three times with Wash Buffer and blot dry with absorbent paper. Dilute Streptavidin-HRP at a 1:100 ratio in diluent and add 20 μL per well to the standard and sample wells. Centrifuge and incubate at room temperature for 30 minutes. Wash the ELISA plate five times with Wash Buffer and blot dry with absorbent paper. Add 20 μL of 1× TMB solution to the standard and sample wells and incubate in the dark for 15 minutes. At the end of incubation, add 20 μL of stop solution. Measure the absorbance of each well at 450 nm and 570 nm, and calculate the absorbance difference.

[0069] Comparing the IL-6 concentrations in the THP-1 cell supernatant of the blank control group and the model group (S protein group), it was found that the blank control group produced almost no IL-6, while the IL-6 concentration in the model group was significantly increased (P<0.05), indicating that the induction of THP-1 cells with S protein in the model group would significantly increase the IL-6 expression level of THP-1 cells. Comparing the IL-6 concentrations in the cell supernatant after the model group was given extracts of the Chinese herbal tea composition at different concentrations, it was found that the IL-6 expression level of THP-1 cells in the model group was significantly decreased after administration, and it also showed a good anti-inflammatory effect at the lowest administration concentration (20μg / mL). At the same time, the anti-inflammatory effect of the extract of the Chinese herbal tea composition was concentration-dependent. The higher the concentration, the stronger the anti-inflammatory effect on the inflammatory model THP-1 cells. When the administration was >200μg / mL, the IL-6 expression level of the inflammatory THP-1 cells was close to that of the normal THP-1 cells. The IL-6 expression of the model group, blank control group and Chinese herbal tea composition under different concentration administration conditions in different culture media is shown in Figure 2. Figure 2 .

[0070] Experiment 5: Anti-inflammatory effect of drug-containing rat serum on RAW264.7 cells (1) Preparation of drug-containing serum samples: 4 SD rats (250-300 g) were fed with the water extract of the Chinese herbal tea composition of Example 1 after one week of adaptive feeding. The rats were given 6 g of the water extract of the Chinese herbal tea composition of Example 1 per day. The normal human body mass is 60 kg, and the equivalent dose for rats is equivalent to 6.3 times that of humans. The oral dose for rats was 270.522 mg / kg. The rats were given the drug once a day by oral gavage for 7 consecutive days. Three hours after the last dose, the rats were anesthetized and blood was collected from the inferior vena cava. The blood sample was allowed to stand at room temperature for 3 hours and then centrifuged at 3000 rpm for 15 minutes. The serum was separated under sterile conditions, filtered with a 0.22 μm filter membrane, inactivated at 56°C for 30 minutes, and stored at -80°C after packaging.

[0071] (2) Effects of different concentrations of drug-containing serum on RAW264.7 cell viability: RAW264.7 cells under optimal growth conditions were centrifuged and resuspended, and the cell suspension was diluted to 2×10 5Cells were plated at 100 μl per well in three 96-well plates. The plates were then placed in a cell culture incubator and incubated for 24 hours at 37°C and 5% carbon dioxide to allow attachment. After observing cell morphology under a microscope, the culture medium was systematically replaced with complete culture medium containing specific volume ratios (1%, 2%, 5%, 10%, and 15%) of drug-containing serum. Each well was plated in triplicate. Cells were cultured in the cell culture incubator for an additional 24 hours before being treated with drugs again at 37°C and 5% carbon dioxide for another 24 hours. After removing the supernatant, 100 μl of 10% Cell Counting Kit-8 (diluted in DMEM) was added to each well, and the cells were incubated at 37°C for 30 minutes in the absence of light. Absorbance was then measured at 450 nm to determine cell viability and determine the appropriate concentration for drug administration.

[0072] (3) Anti-inflammatory effects of different concentrations of drug-containing serum on LPS-induced RAW264.7 cells: RAW264.7 cells under optimal growth conditions were centrifuged, resuspended, and adjusted to 2×10 per ml. 5 Cells were plated at a density of 100 cells / well in complete DMEM medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin. The cell suspension was then carefully seeded into 96-well plates (100 μl per well) and incubated at 37°C, 5% CO2 for 24 hours to ensure adequate cell attachment. After confirming cell viability and morphology under a microscope, three parallel treatments were applied: drug-containing serum groups (2%, 5%, and 10% drug-containing serum to complete DMEM volume ratios, respectively), as well as control groups including a blank control (complete DMEM medium), a model control (200 ng / ml LPS), and a positive control (100 μg / ml dexamethasone combined with 200 ng / ml LPS). All treatments exposed to inflammatory conditions received 200 ng / ml LPS, and each condition was performed in triplicate. The plates were then returned to the incubator (37°C, 5% CO2) for an additional 24-hour incubation period to assess the cytotoxic and anti-inflammatory effects of the test compounds. After incubation, cells were examined microscopically to assess morphological changes and initial treatment effects, followed by subsequent quantitative analysis.

[0073] (4) Detection of nitric oxide (NO) and inflammatory factor IL-6 levels in LPS-induced RAW264.7 cells using different concentrations of drug-containing serum: 50 μl of supernatant culture medium was added with reagents I and II of the nitric oxide assay kit, respectively. The samples were protected from light and the absorbance was measured at 540 nm to calculate the nitric oxide content. The inflammatory factor IL-6 level in the samples was determined according to the instructions of the mouse IL-6 uncoated ELISA kit.

[0074] After preliminary analysis of the nitric oxide (NO) content in RAW264.7 cells induced by lipopolysaccharide (LPS) treated with different volume ratios of drug-containing serum, the expression level of the inflammatory cytokine IL-6 was further studied. By measuring the nitric oxide (NO) content, the anti-inflammatory effect of different volume ratios of drug-containing serum on LPS-induced RAW264.7 cells was preliminarily analyzed. The results are as follows: Figure 3 The results showed that compared with the model group, the drug-containing serum of the low, medium and high dose groups significantly reduced the NO level.

[0075] Figure 3 The results of IL-6 content detection were also presented. The data showed that compared with the model group, the drug-containing serum in the low, medium and high dose groups significantly reduced the IL-6 level. These results indicate that the anti-inflammatory effect of the drug-containing serum is concentration-dependent, and higher concentrations show stronger anti-inflammatory activity in LPS-induced RAW264.7 cells. These findings indicate that the drug-containing serum has a significant anti-inflammatory effect on LPS-induced RAW264.7 cells. Compared with the LPS group, P < 0.001, P < 0.01, P<0.05.

[0076] The above experimental results demonstrate that the medicinal and edible Chinese herbal tea composition using the ingredients described herein, by controlling the components and their ratios, enables better synergy between the components, thereby enhancing the efficacy of treating viral pneumonia. Efficacy experiments have demonstrated that the medicinal tea composition of the present invention has a good anti-inflammatory effect. These characteristics confirm that the raw materials for the medicinal and edible Chinese herbal tea composition are readily available and highly safe, making it suitable for long-term use by the public. The tea has a clear color and a mellow, sweet flavor, and is more durable and compliant than a single dose of decoction, allowing for the integration of daily tea drinking with health care.

[0077] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, rather than to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions of the technical solution of the present invention by ordinary technicians in this field do not deviate from the essence and scope of the technical solution of the present invention.

Claims

1. A Chinese medicinal tea composition for improving viral pneumonia, characterized in that: The invention comprises the following components in parts by weight: 11-18 parts of perilla leaves, 7-13 parts of honeysuckle, 7-13 parts of polygonatum, 5-12 parts of charred hawthorn, 4-8 parts of platycodon, 3-7 parts of tangerine peel, 3-7 parts of liquorice, 3-7 parts of chrysanthemum, 2-5 parts of osmanthus, 0.3-0.6 parts of stevia and 6-14 parts of black tea.

2. The Chinese medicinal tea composition according to claim 1, characterized in that The invention comprises the following components in parts by weight: 15 parts of perilla leaves, 10 parts of honeysuckle, 10 parts of polygonatum, 8 parts of charred hawthorn, 6 parts of platycodon, 5 parts of tangerine peel, 3 parts of liquorice, 5 parts of chrysanthemum, 3 parts of osmanthus, 0.4 parts of stevia and 11 parts of black tea.

3. The Chinese medicinal tea composition according to claim 1, characterized in that The invention is composed of the following components in parts by weight: 11-18 parts of perilla leaves, 7-13 parts of honeysuckle, 7-13 parts of polygonatum, 5-12 parts of charred hawthorn, 4-8 parts of platycodon, 3-7 parts of tangerine peel, 3-7 parts of licorice, 3-7 parts of chrysanthemum, 2-5 parts of osmanthus, 0.3-0.6 parts of stevia and 6-14 parts of black tea.

4. The Chinese medicinal tea composition according to claim 3, characterized in that The invention is composed of the following components in parts by weight: 15 parts of perilla leaves, 10 parts of honeysuckle, 10 parts of polygonatum, 8 parts of charred hawthorn, 6 parts of platycodon, 5 parts of tangerine peel, 3 parts of liquorice, 5 parts of chrysanthemum, 3 parts of osmanthus, 0.4 parts of stevia and 11 parts of black tea.

5. The method for preparing the Chinese medicinal tea composition according to any one of claims 1 to 4, characterized in that: Including steps: (1) Dry, crush and sieve perilla leaves, honeysuckle, polygonatum, charred hawthorn, platycodon, tangerine peel, liquorice, chrysanthemum and stevia; dry osmanthus and black tea; (2) The ingredients of step (1) are mixed and sieved to obtain a Chinese herbal tea composition.

6. The preparation method according to claim 5, characterized in that In step (1), the mesh size of the sieving is 30-60 meshes.

7. The preparation method according to claim 5, characterized in that Step (2) also includes a packaging step.

8. Use of the Chinese medicinal tea composition according to any one of claims 1 to 4 or the Chinese medicinal tea composition prepared by the preparation method according to any one of claims 5 to 7 in preparing a product having the effect of improving viral pneumonia.

9. A product having the effect of improving viral pneumonia, characterized in that: The invention comprises the following components: the Chinese medicinal tea composition according to any one of claims 1 to 4 or the Chinese medicinal tea composition prepared by the preparation method according to any one of claims 5 to 7.

10. The product according to claim 9, characterized in that The products include Chinese herbal tea, Chinese herbal granules, and Chinese herbal beverages.

Images